ArticleThe Korean journal of hematology2012

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma.

Jae-Cheol Jo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.